Back to School: How biopharma can reboot drug development. Access exclusive analysis here

0916 ECP Graphite EMBARGO 8AM ET Weds
BioCentury & Getty Images

Emerging Company Profile

Graphite launches with $45M series A to use CRISPR-Cas9 for targeted gene integration

Matthew Porteus’ Stanford spinout aims to tackle one of CRISPR’s biggest challenges

Stanford spinout Graphite Bio launches with a $45 million series A round to use CRISPR-Cas9 for targeted gene integration.

Sep 16, 2020 | 1:10 PM GMT

Matthew Porteus’ latest gene editing play Graphite Bio launched with a $45 million series A round and a technology to tackle one of the biggest challenges

Read the full 866 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE